Skip to main content

Research

The latest research in type 1 diabetes, type 2 diabetes, prediabetes, and beyond. Here you’ll find information on experimental therapies, new data and results, and scientific findings.

What's new

The RADIANT study aims to define unusual forms of diabetes, to help diagnose and treat these conditions. RADIANT is recruiting people who have been diagnosed with diabetes but don’t fit the usual characteristics of type 1 or type 2 diabetes. Continue Reading »

Recent results from Omada Health’s Digital Diabetes Prevention Program show reductions in A1C and body weight over a 12-month period. This digital tool may be especially helpful for people with prediabetes during COVID-19 Continue Reading »

More people with diabetes are taking drugs like Jardiance and Farxiga, originally developed to lower glucose in people with type 2 diabetes, because the latest data confirms that these drugs can protect your kidneys. A therapy still under investigation, finerenone, has been developed to protect the kidneys of people with and without diabetes Continue Reading »

How might exercise affect your blood glucose? The T1-DEXI study hopes to answer this big question with real-world data from over 600 people with type 1 diabetes – including you! If you have type 1 diabetes and are willing to be active for just 150 minutes each week, this is a unique opportunity to participate remotely in large-scale diabetes research. And, it's quick and easy to sign up!​ Continue Reading »

Highlights from last week’s European Association for the Study of Diabetes’ (EASD) virtual 2020 conference included announcements on the Guardian Sensor 4 Continuous Glucose Monitoring (CGM) and the Omnipod 5 Automated Insulin Delivery (AID) system, new data on the importance of time in range, and updated recommendations on SGLT-2s, GLP-1s, and combination therapies Continue Reading »

Experts discussed the greatest challenges in diabetes in 2020, including the COVID-19 pandemic, and the most critical changes we need to make to address them during diaTribe’s Solvable Problems event Continue Reading »

Latest results presented at the European Society of Cardiology conference show that SGLT-2 inhibitor therapies Jardiance and Farxiga clearly lead to heart and kidney health Continue Reading »

In exciting news for digital diabetes prevention programs, a new study showed that highly engaged participants – those who more frequently engaged in food logging, lessons, and physical activity – were more likely to lose weight Continue Reading »

Pages